These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34697065)

  • 1. Fusion of the Paired Box 3 (
    Panagopoulos I; Gorunova L; Andersen K; Lund-Iversen M; Tafjord S; Micci F; Heim S
    Cancer Genomics Proteomics; 2021; 18(6):723-734. PubMed ID: 34697065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic and Molecular Features of a Series of 41 Biphenotypic Sinonasal Sarcomas Expanding Their Molecular Spectrum.
    Le Loarer F; Laffont S; Lesluyes T; Tirode F; Antonescu C; Baglin AC; Delespaul L; Soubeyran I; Hostein I; Pérot G; Chibon F; Baud J; Le Guellec S; Karanian M; Costes-Martineau V; Castain C; Eimer S; Le Bail B; Wassef M; Coindre JM
    Am J Surg Pathol; 2019 Jun; 43(6):747-754. PubMed ID: 30829729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
    Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
    Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
    Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
    J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway.
    Schmitt-Ney M; Camussi G
    PLoS One; 2015; 10(3):e0121474. PubMed ID: 25806826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel PAX3-NCOA1 Fusions in Biphenotypic Sinonasal Sarcoma With Focal Rhabdomyoblastic Differentiation.
    Huang SC; Ghossein RA; Bishop JA; Zhang L; Chen TC; Huang HY; Antonescu CR
    Am J Surg Pathol; 2016 Jan; 40(1):51-9. PubMed ID: 26371783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1.
    Wachtel M; Dettling M; Koscielniak E; Stegmaier S; Treuner J; Simon-Klingenstein K; Bühlmann P; Niggli FK; Schäfer BW
    Cancer Res; 2004 Aug; 64(16):5539-45. PubMed ID: 15313887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.
    Barr FG; Qualman SJ; Macris MH; Melnyk N; Lawlor ER; Strzelecki DM; Triche TJ; Bridge JA; Sorensen PH
    Cancer Res; 2002 Aug; 62(16):4704-10. PubMed ID: 12183429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case.
    Gordon A; McManus A; Anderson J; Fisher C; Abe S; Nojima T; Pritchard-Jones K; Shipley J
    Cancer Genet Cytogenet; 2003 Jan; 140(1):73-7. PubMed ID: 12550764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.
    Sumegi J; Streblow R; Frayer RW; Dal Cin P; Rosenberg A; Meloni-Ehrig A; Bridge JA
    Genes Chromosomes Cancer; 2010 Mar; 49(3):224-36. PubMed ID: 19953635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.
    Kim YY; Gryder BE; Sinniah R; Peach ML; Shern JF; Abdelmaksoud A; Pomella S; Woldemichael GM; Stanton BZ; Milewski D; Barchi JJ; Schneekloth JS; Chari R; Kowalczyk JT; Shenoy SR; Evans JR; Song YK; Wang C; Wen X; Chou HC; Gangalapudi V; Esposito D; Jones J; Procter L; O'Neill M; Jenkins LM; Tarasova NI; Wei JS; McMahon JB; O'Keefe BR; Hawley RG; Khan J
    Nat Commun; 2024 Feb; 15(1):1703. PubMed ID: 38402212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biphenotypic sinonasal sarcoma with PAX3::MAML3 fusion transforming into high-grade rhabdomyosarcoma: report of an emerging rare phenomenon.
    Meyer A; Klubíčková N; Mosaieby E; Grossmann P; Kalmykova A; Koshyk O; Michal M
    Virchows Arch; 2023 Apr; 482(4):777-782. PubMed ID: 36719455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of alveolar rhabdomyosarcoma copy number alterations by single nucleotide polymorphism analysis.
    Lynn M; Shah N; Conroy J; Ennis S; Morris T; Betts D; O'Sullivan M
    Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):213-21. PubMed ID: 24614150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
    Barr FG
    Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pax3 loss of function delays tumour progression in kRAS-induced zebrafish rhabdomyosarcoma models.
    Kahsay A; Rodriguez-Marquez E; López-Pérez A; Hörnblad A; von Hofsten J
    Sci Rep; 2022 Oct; 12(1):17149. PubMed ID: 36229514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].
    Gao H; Ou YL; Zhang KR; Zhang ZB; Wang WL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):42-7. PubMed ID: 17285543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
    Fredericks WJ; Galili N; Mukhopadhyay S; Rovera G; Bennicelli J; Barr FG; Rauscher FJ
    Mol Cell Biol; 1995 Mar; 15(3):1522-35. PubMed ID: 7862145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
    Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
    Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.
    Tonelli R; McIntyre A; Camerin C; Walters ZS; Di Leo K; Selfe J; Purgato S; Missiaglia E; Tortori A; Renshaw J; Astolfi A; Taylor KR; Serravalle S; Bishop R; Nanni C; Valentijn LJ; Faccini A; Leuschner I; Formica S; Reis-Filho JS; Ambrosini V; Thway K; Franzoni M; Summersgill B; Marchelli R; Hrelia P; Cantelli-Forti G; Fanti S; Corradini R; Pession A; Shipley J
    Clin Cancer Res; 2012 Feb; 18(3):796-807. PubMed ID: 22065083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements.
    Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ
    Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.